Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone vs fenofibrate in NAFLD/NASH
IRCT2015120819554N10Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pioglitazone and fenofibrate in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Zanjan University of Medical Sciences. Started Jul 2016; status: completed.
02
Drugs
pioglitazonefenofibrate
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on IRCT2015120819554N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2015120819554N10.